Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Diabetes 66 , 613626 (2017)
NOTE: The GLP-1 drug class is FDA-approved in ages 12+
In a study of young healthy men, dulaglutide, a GLP-1, did not decrease sexual desire
Published Evidence vs Community Protocols Where each AOD-9604 cycle claim comes from Claim AOD-9604 was studied for 12 weeks Published human support Yes, using oral doses Community support Often used as a community timeline How it should be described Published duration, but not a proven SubQ cycle Claim AOD-9604 was studied for 24 weeks Published human support Yes, using oral tablets Community support Sometimes used to justify longer plans How it should be described Published oral trial
SUSTAIN-6 (Semaglutide in Subjects with Type 2 Diabetes) was the next trial published, lending credence to the cardiovascular benefits of semaglutide
Our solution is simple We are offering compounded GLP-1 medications to allow patients to achieve new goals and live healthier lives
